Virax Biolabs Group Ltd

Virax Biolabs Group Ltd

Virax Biolabs Group Ltd is a diagnostics and immunology company listed on the AIM market of the London Stock Exchange. The firm focuses on T-cell testing technologies for viral infections, including COVID-19, hepatitis B, and cytomegalovirus. Its primary product candidate is the Virax ImmPrint platform, designed to measure cellular immune responses through a blood test. The company was incorporated in the United Kingdom and has disclosed limited information about its management structure or founding timeline. The company's strategy centers on commercializing diagnostic tools for infectious disease monitoring. Virax Biolabs has reported development-stage work on its T-cell assay platform but has not disclosed substantial revenue generation or clinical trial results in peer-reviewed journals. The firm's asset-class exposure is limited to its own equity and development-stage investments. No named portfolio companies, co-investors, or external fund commitments have been confirmed. As of 2025, Virax Biolabs Group Ltd remains a small-cap public company with no publicly available data on team size, assets under management, or institutional investor base. The firm's public filings indicate it has raised capital through equity placements on AIM. No adjacent vehicles, such as foundations or operating businesses, have been disclosed in public records. Virax Biolabs' structural differentiator is its focus on T-cell diagnostics within a small-cap public equity structure, which offers liquidity through the AIM exchange. The firm has not provided transparency on its corporate governance or succession planning. Its limited public profile makes it distinct from larger family offices or asset managers that operate with broader mandates.